Saturday 17 October 2026
Export CAMP’s income statement to Excel — free account
CAMP4 Therapeutics Corporation
CAMP Healthcare Biotechnology
CAMP4 Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, up 436.5% from fiscal 2024. In the quarter to June 2026, revenue grew 18.8%, EPS grew 6.45% and free cash flow fell 23.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.17
0.28
−8.12%
Follow CAMP
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | |
|---|---|---|---|---|
Piotroski F-Score |
4 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
(2.32) | (4.18) | — | — |
P/S ratio |
53.24 | 0.00 | 0.00 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(4.88) | (4.24) | (9.55) | — |
P/Operating CF |
29.59 | (2.17) | (0.62) | — |
P/B ratio |
3.90 | 0.39 | 0.00 | — |
Price to Tangible BV |
3.90 | 0.39 | 0.00 | — |
EV/Sales |
21.56 | 0.00 | 0.00 | — |
EV/EBITDA |
0.00 | 0.76 | 0.00 | — |
EV/Operating CF |
(2.55) | 0.87 | (0.08) | — |
EV/FCF |
(2.53) | 0.86 | (0.08) | — |
Quick Ratio |
7.15 | 6.67 | 4.92 | 10.47 |
Current Ratio |
7.35 | 6.92 | 5.13 | 10.62 |
Net Debt/EBITDA |
2.18 | 1.24 | 0.76 | 1.88 |
Debt/Assets |
0.00% | 0.09% | 0.27% | 0.14% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.04 | 0.01 | 0.00 | — |
Operating CF/Net income |
0.37 | 0.88 | 0.90 | 0.87 |
Capex/Depreciation |
(0.15) | (0.26) | (0.40) | (4.58) |
| (145.07%) | 170.97% | 48.98% | 0.00% | |
| (82.00%) | (77.73%) | (62.59%) | 0.00% | |
ROIC |
0.00% | 0.00% | (17,526.69%) | (1,790.30%) |
Return on Tangible Assets |
(79.67%) | (85.40%) | (133.21%) | (53.82%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
1,092.11% | 5,953.53% | 11,604.57% | 0.00% |
Selling, General and Administrative Expense of Revenue |
496.20% | 2,288.80% | 3,318.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
114.29% | 618.40% | 830.57% | 0.00% |
Graham Net Nets |
0.24 | 2.09 | (2.12) | — |
Graham Number |
0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(43.39%) | (211.56%) | (988.52%) | — |
Free Cash Flow Yield |
(16.00%) | (187.90%) | (777.83%) | — |
Revenue per Share |
0.12 | 0.14 | 0.89 | 0.00 |
Operating CF per Share |
(0.97) | (9.71) | (111.78) | (123.42) |
Capex per Share |
(0.01) | (0.09) | (1.72) | (12.89) |
Free Cash Flow per Share |
(0.98) | (9.81) | (113.50) | (136.30) |
Cash per Share |
3.65 | 13.65 | 97.16 | 266.38 |
Shareholders Equity per Share |
1.57 | 13.46 | 97.26 | 270.94 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.57 | 13.46 | 97.26 | 270.94 |
Free Cash Flow |
(29.80) | (46.00) | (44.83) | (42.57) |
Working Capital |
98.58 | 56.79 | 32.21 | 76.46 |
Capital Expenditures |
(0.24) | (0.44) | (0.68) | (4.02) |
Net Current Asset Value |
43.99 | 51.22 | 23.48 | 66.44 |
EV/EBIT |
0.00 | 0.74 | 0.00 | — |
Capex to Sales |
0.07 | 0.68 | 1.94 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — |
| Other line items | ||||
Depreciation/Fixed assets |
0.70 | 0.44 | 0.35 | 0.16 |
Cash ROIC |
(18.79%) | (36.15%) | (58.27%) | (25.35%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
0.70 | 1.13 | 1.60 | — |
Average Assets |
98.06 | 66.63 | 78.75 | — |
Average Common Equity |
55.42 | (30.29) | (100.63) | — |
Columns are period end dates